DCX Systems Fully Utilizes Rs. 400 Crore IPO Funds with Board-Approved Reallocation and Timeline Extension
CARE Ratings confirms no unutilized IPO proceeds as of September 30, 2026; fund use revised with shareholder consent
DCX Systems Limited has fully utilized the Rs. 400 crore raised through its Initial Public Offering (IPO). Following shareholder approval, the company reallocated funds between subsidiary investment and general corporate purposes, and extended the utilization timeline for general corporate purposes until fiscal year 2029. Monitoring agency CARE Ratings reported no deviations beyond approved revisions or unutilized IPO proceeds as of September 30, 2026.
DCX Systems Limited
Legal / Regulatory
DCX Systems Limited has completed the full utilization of the Rs. 400 crore raised from its IPO by September 30, 2026, following fund reallocation approved by shareholders and timeline extension for certain expenditures.
The company raised Rs. 400 crore through a public fresh issue of 1,93,23,671 equity shares during October 31 to November 2, 2022.
Originally, the IPO proceeds were allocated for repayment of borrowings, funding working capital, capital expenditure including investment in subsidiary Renal Advanced Systems Private Limited (RASPL), and general corporate purposes.
The fund allocation was modified with shareholder approval obtained through postal ballot on May 6, 2024, reducing planned investment in RASPL from Rs. 44.88 crore to Rs. 19.80 crore, and increasing the general corporate purpose allocation from Rs. 58.15 crore to Rs. 83.23 crore.
The purpose of the investment in the subsidiary was revised from capital expenditure to loan repayment.
The timeline for utilizing the general corporate purpose funds was extended by board resolution on February 12, 2026, until fiscal year 2029, due to delays compared to the originally expected timeline of March 2026 for this usage segment, although overall IPO proceeds have been fully utilized as of September 30, 2026, as confirmed by CARE Ratings Limited, the appointed Monitoring Agency.
Highlights
- Full utilization of Rs. 400 crore IPO proceeds by September 30, 2026.
- Shareholders approved fund reallocation on May 6, 2024, reducing subsidiary investment and increasing general corporate purpose funds.
- Purpose of subsidiary investment changed to loan repayment from capital expenditure.
- Timeline for utilizing general corporate purpose funds extended to fiscal year 2029 by board resolution.
- No deviations from approved utilization beyond authorized changes.
- Monitoring Agency CARE Ratings Limited issued the utilization report confirming completion.
Key Data Snapshot
What happened
- DCX Systems raised Rs. 400 crore through a public fresh issue in late 2022.
- The company has fully utilized all IPO proceeds by September 30, 2026.
- Monitoring agency CARE Ratings Limited confirmed no unutilized funds remained as of this date.
Key details
- The original offer included investment in subsidiary Renal Advanced Systems Private Limited and general corporate purposes.
- Shareholder approval was obtained for reallocating funds, notably reducing subsidiary investment and increasing general corporate purposes.
- The intended subsidiary investment purpose changed from capital expenditure to loan repayment.
- Timeline for spending general corporate purpose funds was extended to fiscal year 2029 from an original target of March 2026.
- The company provided the required Monitoring Agency reports per SEBI regulations until full utilization was confirmed.
Regulatory and governance context
- The monitoring agency report is submitted as per SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2015.
- No deviations beyond those approved by shareholders were noted in the period ending September 30, 2026.
- The monitoring agency report is based on information provided by the company and is not an independent audit.
Highlights
- Full utilization of Rs. 400 crore IPO proceeds by September 30, 2026.
- Shareholders approved fund reallocation on May 6, 2024, reducing subsidiary investment and increasing general corporate purpose funds.
- Purpose of subsidiary investment changed to loan repayment from capital expenditure.
- Timeline for utilizing general corporate purpose funds extended to fiscal year 2029 by board resolution.
- No deviations from approved utilization beyond authorized changes.
- Monitoring Agency CARE Ratings Limited issued the utilization report confirming completion.
Disclosures
- SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
- SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2015
Dr. H S Raghavendra Rao, NCBG Holdings Inc, and Raneal Technologies Private Limited are identified promoters of DCX Systems Ltd.
More News on Legal / Regulatory
View allLatest corporate announcements and market updates in Legal / Regulatory.
J.K. Shah Commerce Education Limited Implements Insider Trading Prohibition Code under SEBI Regulations
J.K. Shah Commerce Education Limited has formally adopted its Insider Trading Prohibition Code, incorporating a comprehensive framework to regulate, monitor, and report insider trading activities, including safeguards for handling unpublished price-sensitive information, as mandated by SEBI regulations.
Read Full StoryThe India Cements' ₹26.40 Crore Arbitral Award Confirmed as Supreme Court Dismisses Zuari Cement's Petition
The India Cements Limited announced that the Supreme Court of India dismissed Zuari Cement Limited's Special Leave Petition dated 18 November 2026, confirming the arbitral award of ₹26.40 crore plus interest awarded to The India Cements in a marketing agreement dispute.
Read Full StoryNHPC Settles ₹42.62 Crore Arbitration Claim with Patel-L&T Consortium for Parbati-III Project Delay
NHPC has finalized a settlement agreement with Patel-L&T Consortium in an arbitration related to delay and adverse geological conditions impacting the Parbati-III Hydro Electric Project. The final settlement amount of ₹42.62 Crore replaces the initial claim of ₹256.10 Crore and was paid on 17 November 2026.
Read Full Story